(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 24.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.15%.
Regenxbio's revenue in 2026 is $174,482,000.On average, 14 Wall Street analysts forecast RGNX's revenue for 2026 to be $11,197,817,759, with the lowest RGNX revenue forecast at $8,307,100,081, and the highest RGNX revenue forecast at $20,724,841,628. On average, 13 Wall Street analysts forecast RGNX's revenue for 2027 to be $14,093,156,360, with the lowest RGNX revenue forecast at $1,811,401,988, and the highest RGNX revenue forecast at $29,009,497,224.
In 2028, RGNX is forecast to generate $23,173,270,920 in revenue, with the lowest revenue forecast at $11,746,387,384 and the highest revenue forecast at $41,518,997,108.